Opinion|Videos|November 16, 2026

Inside DPP-1 inhibition: A new oral anti-inflammatory mechanism for bronchiectasis

Author(s)Marc Sala, MD

DPP-1 inhibitors are oral small molecules that block the enzyme responsible for activating neutrophil elastase, and in the pivotal ASPEN trial, brensocatib reduced annualized exacerbations by about 20% versus placebo.

DPP-1 inhibitors — dipeptidyl peptidase-1 inhibitors — are the newest class of medication available for bronchiectasis, Sala said. These oral small molecules inhibit DPP-1, an enzyme that activates neutrophil serine proteases, including neutrophilic elastase. He walked through the underlying biology: neutrophils mature in the bone marrow, are released, and migrate to sites of inflammation. In people with bronchiectasis, these neutrophils home into the airways and, due to what appears to be a genetically programmed tendency, linger there far longer than they should, contributing to excess inflammation and flares. A DPP-1 inhibitor interrupts that process by preventing activation and release of neutrophilic elastase, curbing the resulting inflammation.

Sala positioned the drug class as directly tied to the neutrophilic inflammation pathway discussed earlier in the interview. Currently, only one DPP-1 inhibitor is available on the market, giving clinicians a second anti-inflammatory option beyond azithromycin for the first time.

The pivotal evidence comes from the ASPEN trial, a multicenter, global study sponsored by Insmed evaluating brensocatib at two doses against placebo. The primary outcome showed an approximately 20% reduction in the annualized rate of exacerbations across both doses studied. In a field where exacerbations carry such high clinical and patient significance, Sala called this a meaningful innovation.


Related to this article